<SEC-DOCUMENT>0001213900-24-075803-index.html : 20240905
<SEC-HEADER>0001213900-24-075803.hdr.sgml : 20240905
<ACCEPTANCE-DATETIME>20240905092230
ACCESSION NUMBER:		0001213900-24-075803
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231211
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240905
DATE AS OF CHANGE:		20240905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aditxt, Inc.
		CENTRAL INDEX KEY:			0001726711
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				823204328
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39336
		FILM NUMBER:		241280127

	BUSINESS ADDRESS:	
		STREET 1:		737 N. FIFTH STREET, SUITE 200
		CITY:			RICHMOND
		STATE:			VA
		ZIP:			23219
		BUSINESS PHONE:		909-488-0844

	MAIL ADDRESS:	
		STREET 1:		737 N. FIFTH STREET, SUITE 200
		CITY:			RICHMOND
		STATE:			VA
		ZIP:			23219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aditx Therapeutics, Inc.
		DATE OF NAME CHANGE:	20201113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADiTx Therapeutics, Inc.
		DATE OF NAME CHANGE:	20171229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>ea0213049-8ka2_aditxt.htm
<DESCRIPTION>AMENDMENT NO. 2 TO FORM 8-K
<TEXT>
Document 1 - file: ea0213049-8ka2_aditxt.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>2 <FILENAME>ea021304901ex99-1_aditxt.htm <DESCRIPTION>UNAUDITED FINANCIAL STATEMENTS OF EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES AS OF AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 AND 2023 <TEXT> Document 2 - file: ea021304901ex99-1_aditxt.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>3 <FILENAME>ea021304901ex99-2_aditxt.htm <DESCRIPTION>UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2024 <TEXT> Document 3 - file: ea021304901ex99-2_aditxt.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-101.SCH <SEQUENCE>4 <FILENAME>adtx-20231211.xsd <DESCRIPTION>XBRL SCHEMA FILE <TEXT> Document 4 - file: adtx-20231211.xsd
</DOCUMENT> <DOCUMENT> <TYPE>EX-101.LAB <SEQUENCE>5 <FILENAME>adtx-20231211_lab.xml <DESCRIPTION>XBRL LABEL FILE <TEXT> Document 5 - file: adtx-20231211_lab.xml
</DOCUMENT> <DOCUMENT> <TYPE>EX-101.PRE <SEQUENCE>6 <FILENAME>adtx-20231211_pre.xml <DESCRIPTION>XBRL PRESENTATION FILE <TEXT> Document 6 - file: adtx-20231211_pre.xml
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>8 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 8 - file: R1.htm
</DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>9 <FILENAME>Financial_Report.xlsx <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 9 - file: Financial_Report.xlsx
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>10 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 10 - file: Show.js
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>11 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 11 - file: report.css
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>13 <FILENAME>FilingSummary.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 13 - file: FilingSummary.html
Document 13 - RAW XML: FilingSummary.xml
</DOCUMENT> <DOCUMENT> <TYPE>JSON <SEQUENCE>15 <FILENAME>MetaLinks.json <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 15 - file: MetaLinks.json
</DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>16 <FILENAME>0001213900-24-075803-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 16 - file: 0001213900-24-075803-xbrl.zip
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>17 <FILENAME>ea0213049-8ka2_aditxt_htm.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 17 - file: ea0213049-8ka2_aditxt_htm.html
Document 17 - RAW XML: ea0213049-8ka2_aditxt_htm.xml
</DOCUMENT> </SEC-DOCUMENT>